Mr. Jinsheng Ren founded Simcere Pharmaceutical Group in 1995 and has been one of the top leaders in Chinese local pharmaceutical enterprises since then. Simcere now is one of the leading R&D-driven pharmaceutical companies in China, with full value chain capacity of drug development from innovation, manufacture and commercialization. It has been ranked as one of the top 10 of the most innovative pharmaceutical companies in China in the past few years.
Prior to the significant move of his career, he was the department head of Jiangsu Pharmaceutical Industrial Co. and earlier worked at Gaitianli Pharmaceutical as Vice General Manager. Currently, Mr. Ren is the Chairman and CEO of Simcere and the group successfully went public in Hong Kong in 2020 under his leadership. In addition to the roles inside Simcere, he is also the Vice President of the ninth committee of Jiangsu Association for Science and Technology.
Mr. Ren received his master’s degree in Economics from Macquarie University and previously graduated from Nanjing University of Chinese Medicine. To reward his contributions to both the academia and industry in China, several universities have invited him to be either visiting professor or adjunct professor, such as, China Pharmaceutical University, Nanjing University of Chinese Medicine, and Northwest University (China).